Walgreens (WBA.US) stock briefly jumped nearly 7.0% in the premarket after the drugstore operator posted better-than-expected quarterly profit and revenue. The company also raised its long-term sales targets.
- The drugstore chain earned 80 cents per share, down 31.6% from the same period last year, however 3 cents above analysts’ estimates. Revenues dropped 5.3% from last year to $32.4 billion, beating market consensus of a $32.085 billion tally, as U.S. same-store sales rose 1.6%.
- Comparable sales at Boots, its U.K.-based division, jumped 15.2% from last year, even amid a 6.9% slump in overall pharmacy revenues.
- When it comes to fiscal 2023, the company expects adjusted EPS of $4.45 to $4.65, in the midpoint of the FactSet projections of $4.51. U.S. Healthcare fiscal 2025 sales target was lifted to $11 billion to $12 billion from $9 billion to $10 billion.
Walgreens (WBA.US) stock plunged over 14.0% within the past three months. Stock rose sharply before the opening bel, however most of the gains were erased after US CPI release. Currently price is trading near the upper limit of the local descending channel. However if current sentiment prevails, another downward move may be launched towards recent lows at $30.45. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
